DC Field | Value | Language |
---|---|---|
dc.contributor.author | D S Kim | - |
dc.contributor.author | Sangku Lee | - |
dc.contributor.author | H K Lee | - |
dc.contributor.author | S H Park | - |
dc.contributor.author | In Ja Ryoo | - |
dc.contributor.author | Ick Dong Yoo | - |
dc.contributor.author | S B Kwon | - |
dc.contributor.author | J B Kwang | - |
dc.contributor.author | J I Na | - |
dc.contributor.author | K C Park | - |
dc.date.accessioned | 2017-04-19T09:09:39Z | - |
dc.date.available | 2017-04-19T09:09:39Z | - |
dc.date.issued | 2008 | - |
dc.identifier.issn | 0022-3573 | - |
dc.identifier.uri | 10.1211/jpp.60.3.0009 | ko |
dc.identifier.uri | https://oak.kribb.re.kr/handle/201005/8332 | - |
dc.description.abstract | Resorcinol derivatives are known to inhibit melanin synthesis. In this study, resorcinol derivatives were synthesized and screened for their activity on melanogenesis. KI-063 (a tyrosinase inhibitor) was examined for its effects on melanogenesis using a spontaneously immortalized mouse melanocyte cell line (Mel-Ab). In a cell-free system, KI-063 directly inhibited tyrosinase, the rate-limiting melanogenic enzyme. Moreover, in a cell system, it inhibited melanin synthesis in a concentration-dependent manner. In addition, KI-063 inhibited the activity of cellular tyrosinase. Thus, this study examined the effects of a combination of KI-063 with terrein, an agent that down-regulates microphthalmia-associated transcription factor. The data suggest that KI-063 has an additive effect in combination with terrein. Thus, the suppression of tyrosinase activity by KI-063 and the inhibition of tyrosinase production by terrein appear to be an optimal combination for skin whitening. | - |
dc.publisher | Wiley | - |
dc.title | The hypopigmentary action of KI-063 (a new tyrosinase inhibitor) combined with terrein | - |
dc.title.alternative | The hypopigmentary action of KI-063 (a new tyrosinase inhibitor) combined with terrein | - |
dc.type | Article | - |
dc.citation.title | Journal of Pharmacy and Pharmacology | - |
dc.citation.number | 3 | - |
dc.citation.endPage | 348 | - |
dc.citation.startPage | 343 | - |
dc.citation.volume | 60 | - |
dc.contributor.affiliatedAuthor | Sangku Lee | - |
dc.contributor.affiliatedAuthor | In Ja Ryoo | - |
dc.contributor.affiliatedAuthor | Ick Dong Yoo | - |
dc.contributor.alternativeName | 김 | - |
dc.contributor.alternativeName | 이상구 | - |
dc.contributor.alternativeName | 이 | - |
dc.contributor.alternativeName | 박 | - |
dc.contributor.alternativeName | 류인자 | - |
dc.contributor.alternativeName | 유익동 | - |
dc.contributor.alternativeName | 권 | - |
dc.contributor.alternativeName | 강 | - |
dc.contributor.alternativeName | 나 | - |
dc.contributor.alternativeName | 박 | - |
dc.identifier.bibliographicCitation | Journal of Pharmacy and Pharmacology, vol. 60, no. 3, pp. 343-348 | - |
dc.identifier.doi | 10.1211/jpp.60.3.0009 | - |
dc.description.journalClass | Y | - |
There are no files associated with this item.
Items in OpenAccess@KRIBB are protected by copyright, with all rights reserved, unless otherwise indicated.